Download PDF
Thromb Haemost 2004; 92(02): 428-430
DOI: 10.1055/s-0037-1613733
Letters to the Editor
Schattauer GmbH

Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin

Bengt I. Eriksson
1   Department of Orthopaedics, Sahlgrenska University Hospital/Östra, Göteborg, Sweden
,
Giancarlo Agnelli
2   University of Perugia, Perugia, Italy
,
Alexander Cohen
3   Guy’s, King’s and St Thomas’ School of Medicine and Dentistry, London, UK
,
Ola Dahl
4   Department of Orthopaedics, Section for Joint Implants and Medical Science Buskerud Central Hospital, Drammen, Norway
,
Patrick Mouret
5   Frankfurt-Höchst Clinic, Frankfurt, Germany
,
Nadia Rosencher
6   Paris M5 University and Cochin University Hospital, Paris, France
,
Seva Panfi-lo
7   AstraZeneca R&D Mölndal, Mölndal, Sweden
,
Magnus Andersson
7   AstraZeneca R&D Mölndal, Mölndal, Sweden
,
the METHRO III Study Investigators › Author AffiliationsFinancial support: This study was supported by a research grant from AstraZeneca, Mölndal, Sweden.
Further Information

Publication History

Received 23 February 2004

Accepted after revision 04 June 2004

Publication Date:
15 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Eriksson BI, Agnelli G, Cohen AT. et al. on behalf of the METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89: 288-296.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Eriksson BI, Bergqvist D, Kalebo P. et al. Ximelagatran and melagatran compared with dalte-parin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447.
    CrossrefPubMedGoogle Scholar
  • 3 Eriksson BI, Agnelli G, Cohen AT. et al. on behalf of the EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: fhe EXPRESS study. J Thromb Haemost 2003; 01: 2490-2496.
    CrossrefPubMedGoogle Scholar